FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604413507> ?p ?o ?g. }

• W2604413507 endingPage "1785" @default.
• W2604413507 startingPage "1778" @default.
• W2604413507 abstract "Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non–small-cell lung cancer (NSCLC). Patients and Methods Using a 3 + 3 + 3 dose-escalation study, nine chemotherapy-naïve patients (five MPM, four NSCLC) received weekly ADI-PEG 20 doses of 18 mg/m 2 , 27 mg/m 2 , or 36 mg/m 2 , together with pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2 which were given every three weeks (maximum of six cycles). Patients achieving stable disease or better could continue ADI-PEG 20 monotherapy until disease progression or withdrawal. Adverse events were assessed by Common Terminology Criteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for NSCLC and by modified RECIST criteria for MPM. Results No dose-limiting toxicities were reported; nine of 38 reported adverse events (all grade 1 or 2) were related to ADI-PEG 20. Circulating arginine concentrations declined rapidly, and citrulline levels increased; both changes persisted at 18 weeks. Partial responses were observed in seven of nine patients (78%), including three with either sarcomatoid or biphasic MPM. Conclusion Target engagement with depletion of arginine was maintained throughout treatment with no dose-limiting toxicities. In this biomarker-selected group of patients with ASS1-deficient cancers, clinical activity was observed in patients with poor-prognosis tumors. Therefore, we recommend a dose for future studies of weekly ADI-PEG 20 36 mg/m 2 plus three-weekly cisplatin 75 mg/m 2 and pemetrexed 500 mg/m 2 ." @default.
• W2604413507 created "2017-04-14" @default.
• W2604413507 creator A5003679842 @default.
• W2604413507 creator A5007808102 @default.
• W2604413507 creator A5018384442 @default.
• W2604413507 creator A5022032908 @default.
• W2604413507 creator A5025554976 @default.
• W2604413507 creator A5027221531 @default.
• W2604413507 creator A5028665323 @default.
• W2604413507 creator A5030439182 @default.
• W2604413507 creator A5034514799 @default.
• W2604413507 creator A5034748028 @default.
• W2604413507 creator A5042869404 @default.
• W2604413507 creator A5049948035 @default.
• W2604413507 creator A5058782121 @default.
• W2604413507 creator A5066051408 @default.
• W2604413507 creator A5070432912 @default.
• W2604413507 creator A5079505616 @default.
• W2604413507 creator A5088428805 @default.
• W2604413507 creator A5089814770 @default.
• W2604413507 creator A5089861374 @default.
• W2604413507 date "2017-06-01" @default.
• W2604413507 modified "2023-10-02" @default.
• W2604413507 title "Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers" @default.
• W2604413507 cites W1588371609 @default.
• W2604413507 cites W1966242225 @default.
• W2604413507 cites W1968138441 @default.
• W2604413507 cites W1970434896 @default.
• W2604413507 cites W1984633408 @default.
• W2604413507 cites W2028937577 @default.
• W2604413507 cites W2031936148 @default.
• W2604413507 cites W2036407487 @default.
• W2604413507 cites W2041076445 @default.
• W2604413507 cites W2043600567 @default.
• W2604413507 cites W2057823163 @default.
• W2604413507 cites W2066858504 @default.
• W2604413507 cites W2070436739 @default.
• W2604413507 cites W2079270053 @default.
• W2604413507 cites W2099725888 @default.
• W2604413507 cites W2102627969 @default.
• W2604413507 cites W2106712645 @default.
• W2604413507 cites W2110195508 @default.
• W2604413507 cites W2112446608 @default.
• W2604413507 cites W2119097025 @default.
• W2604413507 cites W2119785831 @default.
• W2604413507 cites W2129920232 @default.
• W2604413507 cites W2134972696 @default.
• W2604413507 cites W2138841054 @default.
• W2604413507 cites W2147998910 @default.
• W2604413507 cites W2161332892 @default.
• W2604413507 cites W2167874373 @default.
• W2604413507 cites W2168974457 @default.
• W2604413507 cites W2291531085 @default.
• W2604413507 cites W2512678052 @default.
• W2604413507 cites W2565501761 @default.
• W2604413507 cites W262159292 @default.
• W2604413507 cites W4323285563 @default.
• W2604413507 doi "https://doi.org/10.1200/jco.2016.71.3230" @default.
• W2604413507 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6141244" @default.
• W2604413507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28388291" @default.
• W2604413507 hasPublicationYear "2017" @default.
• W2604413507 type Work @default.
• W2604413507 sameAs 2604413507 @default.
• W2604413507 citedByCount "89" @default.
• W2604413507 countsByYear W26044135072017 @default.
• W2604413507 countsByYear W26044135072018 @default.
• W2604413507 countsByYear W26044135072019 @default.
• W2604413507 countsByYear W26044135072020 @default.
• W2604413507 countsByYear W26044135072021 @default.
• W2604413507 countsByYear W26044135072022 @default.
• W2604413507 countsByYear W26044135072023 @default.
• W2604413507 crossrefType "journal-article" @default.
• W2604413507 hasAuthorship W2604413507A5003679842 @default.
• W2604413507 hasAuthorship W2604413507A5007808102 @default.
• W2604413507 hasAuthorship W2604413507A5018384442 @default.
• W2604413507 hasAuthorship W2604413507A5022032908 @default.
• W2604413507 hasAuthorship W2604413507A5025554976 @default.
• W2604413507 hasAuthorship W2604413507A5027221531 @default.
• W2604413507 hasAuthorship W2604413507A5028665323 @default.
• W2604413507 hasAuthorship W2604413507A5030439182 @default.
• W2604413507 hasAuthorship W2604413507A5034514799 @default.
• W2604413507 hasAuthorship W2604413507A5034748028 @default.
• W2604413507 hasAuthorship W2604413507A5042869404 @default.
• W2604413507 hasAuthorship W2604413507A5049948035 @default.
• W2604413507 hasAuthorship W2604413507A5058782121 @default.
• W2604413507 hasAuthorship W2604413507A5066051408 @default.
• W2604413507 hasAuthorship W2604413507A5070432912 @default.
• W2604413507 hasAuthorship W2604413507A5079505616 @default.
• W2604413507 hasAuthorship W2604413507A5088428805 @default.
• W2604413507 hasAuthorship W2604413507A5089814770 @default.
• W2604413507 hasAuthorship W2604413507A5089861374 @default.
• W2604413507 hasBestOaLocation W26044135071 @default.
• W2604413507 hasConcept C126322002 @default.
• W2604413507 hasConcept C143998085 @default.
• W2604413507 hasConcept C164007495 @default.
• W2604413507 hasConcept C185592680 @default.
• W2604413507 hasConcept C188610204 @default.
• W2604413507 hasConcept C197934379 @default.

• next